Insurance, affordability, FDA approvals, access, health policy, and cost-related IBD news.
Page 3 of 3 · 123 articles
Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Access, cost, and policy. Open the original article for the full details.
Access and insurance issues can delay IBD medications and lead patients to skip doses or make financial sacrifices. That can worsen health and daily life, so this affects many people with Crohn’s disease and ulcerative...
Understanding that low patient activation can reflect poor health literacy helps explain disparities in access, diagnosis delays, and outcomes for children with IBD. Improving communication and education could make care...
The article centers on how Crohn’s affects Black people differently because of access barriers, stigma, and underrepresentation—issues that can influence diagnosis, disease severity, and quality of life.
This roundup highlights new IBD research and real-world care issues that could influence future diagnosis, monitoring, and access to treatments. Findings on financial barriers and gaps in treat-to-target monitoring may...
The article summarizes recent drug approvals and Phase 3 trial results that could affect which biologic treatments are available and how the Crohn's disease treatment market may change. It also gives epidemiology and...
Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from firstwordpharma.com.
Based on the title and source metadata, this appears to be a market or business news related to Inflammatory bowel disease and Access, cost, and policy. The original article is from menafn.com.
Fundraising events support IBD research, programs and patient services. Money raised can contribute to work on personalized treatments and diagnostic tools that might benefit people with Crohn’s disease or ulcerative...
A newly approved biologic, Omvoh (mirikizumab), gives another FDA‑approved treatment option for adults with moderate to severe Crohn’s disease and adds to Lilly’s role in IBD care.
The article spotlights duvakitug and the anti‑TL1A drug class as potential new options for ulcerative colitis and Crohn’s disease, especially for treatment‑experienced patients. Biomarker‑driven studies could help...
The event raised funds for the Crohn’s & Colitis Foundation, which supports IBD research, education, and patient care. Community fundraising events can expand local support networks and resources for people living with...
This article is a market research summary about the global Crohn’s disease treatment market — it describes sales forecasts, industry players, and market trends rather than new clinical findings or patient-focused...
The article reports that many people with IBD face unaffordable care and medication access problems that can lead to nonadherence and worse health. It offers practical steps to manage costs now and calls for policy...
Based on the title and source metadata, this appears to be a market or business news related to Access, cost, and policy. The original article is from seekingalpha.com.
This gives adults with moderately to severely active Crohn’s disease another FDA‑approved biologic option, including for people who did not respond to or could not tolerate other therapies.
A new FDA approval means another biologic option for people with moderately to severely active Crohn’s disease, including patients who have failed or not tolerated prior therapies.
Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Access, cost, and policy. The original article is from...
An FDA approval means another biologic option is available for Crohn’s disease, which could affect treatment choices and insurance coverage. The approval also signals pharma competition and pipeline activity that may...
An FDA approval means Omvoh is now an available biologic option for adults with Crohn’s disease, potentially expanding treatment choices. Payer decisions mentioned in the article could affect how quickly patients can...
A new FDA-approved treatment option is now available for adults with moderately to severely active Crohn’s disease, including people who’ve not responded to or tolerated prior therapies. Approval was supported by phase 3...
A new FDA-approved biologic option (Omvoh/mirikizumab) is now available for adults with moderately to severely active Crohn’s disease, potentially expanding treatment choices.
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
FDA approval means mirikizumab (Omvoh) is now an available biologic option in the US for adults with moderately to severely active Crohn’s disease, especially for people who did not respond to standard treatments. It may...
A newly FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderately to severely active Crohn's disease another targeted treatment option. It's the same IL-23–targeting drug already approved for ulcerative...
At‑home tests that claim to identify food triggers for IBS or related gut conditions may influence how people manage symptoms. Patents covering tests for Crohn’s and ulcerative colitis suggest the company is aiming to...
Clinical trials expand treatment options and are how new IBD therapies are tested and approved. Low enrollment can delay access to future treatments for Crohn’s and ulcerative colitis.
